Live cumulative network meta-analysis: protocol for second-line treatments in advanced non-small-cell lung cancer with wild-type or unknown status for epidermal growth factor receptor

摘要: Introduction Many second-line treatments for advanced non-small-cell lung cancer (NSCLC) have been assessed in randomised controlled trials, but which work the best remains unclear. Novel are being rapidly developed. We need a comprehensive up-to-date evidence synthesis of all these treatments. present protocol live cumulative network meta-analysis (NMA) to address this need. Methods and analysis will consider trials patients with NSCLC wild-type or unknown epidermal growth factor receptor status. any single agent cytotoxic chemotherapy, targeted therapy, combination chemotherapy therapy therapies. The primary outcomes be overall survival progression-free survival. NMA initiated then iterations repeated at regular intervals keep over time. defined update frequency as 4 months, based on an assessment pace production topic. Each iteration consist six methodological steps: adaptive search screening reports selection data extraction, risk bias, synthesis, dissemination. set up research community cancer, different groups contributors skills. distribute tasks through online crowdsourcing. This proof-of-concept study allow one assessing feasibility opening path new form synthesis. Ethics dissemination Ethical approval is not required because our include confidential participant interventions. description steps results available online. Trial registration number CRD42015017592.